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Ji Eun Jang, Shin Young Hyun, Yun Deok Kim, Sul Hee Yoon, Doh Yu Hwang,
Soo Jeong Kim, Yuri Kim, Jin Seok Kim, June-Won Cheong, Yoo Hong MinCytomegalovirus (CMV) disease is a major cause of infectious complications in allogeneic hematopoietic
stem cell transplantation (allo-HSCT). Although patients undergoing allo-HSCT receive prophylactic and
preemptive treatment for CMV, a subset of patients experience clinically significant CMV disease. This study
investigated the risk factors for progression from CMV viremia to CMV disease during or after preemptive
therapy in patients undergoing allo-HSCT. Between January 2006 and August 2010, 43 patients received
preemptive therapy for CMV viremia after allo-HSCT. These patients experienced 74 episodes of CMV
viremia. Nine of the patients (21%) and 12 of the episodes (16%) progressed to CMV disease. Univariate
analysis identified several risk factors for progression to CMV disease, including high initial viral load
(P 5 .020), leukopenia (P 5 .012), and neutropenia (P 5 .033) at the time of detection of CMV viremia.
On multivariate analysis, leukopenia remained an independent predictor (hazard ratio, 4.347; P 5 .045).
The rate of failure to clear CMV viremia after 1 cycle of preemptive therapy was higher in the leukopenia
group than in the non-leukopenia group (60.0% versus 16.9%; P 5 .002). This indicates that leukopenia
initially documented with CMV viremia is related to lower viral response to preemptive therapy and is
a notable risk factor for progression from CMV viremia to CMV disease.
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Cytomegalovirus (CMV) disease is a major cause
of infectious complications after allogeneic hemato-
poietic stem cell transplantation (allo-HSCT) [1].
Even with active CMV prophylaxis provided after
allo-HSCT, a subset of patients experience CMV
infection or reactivation of infection, and CMV-
related mortality is not uncommon. The risk factors
for CMV viremia have been examined in previous
studies [2,3]. Known risk factors for CMV viremia
after allo-HSCT include pretransplantation CMV
serostatus of donor or recipient, development of
graft-versus-host disease (GVHD), ex vivo or in vivoDivision of Hematology, Department of Internal Medi-
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viremia is typically asymptomatic, but CMV disease
may be accompanied by serious clinical signs or
symptoms in affected organs. For example, little
progress has been made in the treatment of CMV
pneumonitis over the past 2 decades [3,8], and a study
from the European Bone Marrow Transplant group
reported only a 31% survival rate at 1 month after
diagnosis [9].
There are few reports on the risk factors for
progression from CMV viremia to CMV disease in
patients receiving preemptive therapy. Increased un-
derstanding of these risk factors could help guide
more effective or intensive therapy before the develop-
ment of CMV disease. Accordingly, the present study
investigated the risk factors for progression from
CMV viremia to CMV disease after allo-HSCT.PATIENTS AND METHODS
Patients
Between June 2006 and August 2010, 114 patients
underwent allo-HSCT at SeveranceHospital in Seoul,
Korea. Among these patients, those who received881
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analysis. CMV viremia was detected in 43 patients,
who had a total of 74 viremic episodes, and these pa-
tients’ medical records were reviewed retrospectively.
CMV Prophylaxis
Acyclovir (250mg i.v. 3 times daily) was given to all
patients as prophylaxis from the day of initiation of
conditioning chemotherapy to day 14 after allo-
HSCT, followed by oral dosing (400 mg twice daily)
for 9 months. All patients received i.v. polyvalent im-
munoglobulin (0.5 g/kg every 2 weeks) for 3 months,
then every 4 weeks for the subsequent 6 months.
CMV Monitoring and Preemptive Therapy
All patients were monitored by CMV-specific
qualitative PCR. If qualitative PCR was positive,
then quantitative PCR was performed to determine vi-
ral load. Patients were monitored every week for the
first month, then every 2-4 weeks until the end of treat-
ment with immunosuppressive agents or the resolution
of GVHD. If the viral load exceeded 5000 copies/mL
or qualitative PCR was positive in 2 consecutive tests,
then preemptive therapy was started with ganciclovir 5
mg/kg i.v. every 12 hours for 14 days (a total of 28
doses). If viremia remained after 14 days of treatment,
then an additional 7 days of treatment was added at the
same dose. Intravenous immunoglobulin was adminis-
tered concurrently.
Blood Cell Count Sampling
A complete blood cell count sampling with differ-
ential WBC count was performed at the detection of
CMV viremia. Leukopenia (WBC #3000/mm3),
neutropenia (neutrophils #1500/mm3), lymphopenia
(lymphocytes #800/mm3), anemia (hemoglobin #10
g/dL), and thrombocytopenia (platelets #75,000/
mm3) were assessed in accordance with the
Common Terminology Criteria for Adverse Events
(CTCAE 4.0).
Definitions
The clearance of CMV viremia was defined as 2
consecutive negative PCR analyses after preemptive
therapy. A recurrent episode of CMV viremia after
clearance of previous viremia was considered a new
episode. Early CMV viremia was defined as viremia
detected before day 100 after allo-HSCT. CMV
disease was defined as confirmation of CMV by an
appropriate method accompanied by documentation
of signs and symptoms in affected organs in patients
who had received preemptive therapy or had a positive
CMVPCR result in the previous month [10,11]. CMV
pneumonitis was defined as clinical symptoms of
pneumonia together with computed tomography
findings consistent with CMV even without detectionof CMV in bronchoalveolar lavage fluid or a lung
tissue sample. CMV gastrointestinal disease was
defined as gastrointestinal symptoms plus histological
evidence of CMV from a gastrointestinal biopsy
specimen. CMV retinitis was diagnosed by the
presence of typical lesions detected by an experienced
ophthalmologist, without the need for isolation of
CMV in the ocular fluid.
Statistical Analysis
Statistical calculations were performed using SPSS
version 18.0 (SPSS Inc, Chicago, IL). Variables were
compared between groups using the Fisher exact test.
Cox regression hazard models were used for multivar-
iate analysis. A P value \.05 was considered
statistically significant.RESULTS
Patient Characteristics
A total of 74 episodes of CMV viremia were
analyzed. The median patient age was 34 years (range,
16-54 years). CMV serostatus of recipient and donor
before transplantation was positive in all episodes. In
all episodes, the underlying disease was leukemia
(49 episodes with acute myelogenous leukemia, 24
episodes with acute lymphoblastic leukemia, and 1
episode with biphenotypic acute leukemia). The donor
was an HLA-matched sibling in 19 episodes (25.7%)
and an HLA-matched unrelated donor in 55 episodes
(74.3%). Stem cell source was peripheral blood in
the majority of cases (89.2%). The conditioning
regimen was myeloablative in 35 episodes (47.3%).
T cell–depleting agents were given in 9 cases (12.2%;
alemtuzumab in 8 and antithymocyte globulin
[ATG] in 1).
Incidence of CMV Viremia and Disease
The median time to detection of viremia in the 74
episodes was 81 days (range, 13-1240 days) after
allo-HSCT. Thirty-four episodes (46%) were de-
tected beyond day 100 after allo-HSCT. Eight
patients experienced 2 episodes of viremia, 8 patients
experienced more than 2 episodes, and 27 patients
experienced a single episode. Of the 43 patients with
detected CMV viremia, 9 (21%) progressed to CMV
disease; and among the 74 epsiodes of CMV viremia,
12 cases of CMV disease developed (16%), including
2 cases of CMV pneumonitis, 3 cases of CMV gastro-
enteritis, and 7 cases (3 recurring) of CMV retinitis.
CMV disease occurred at median of 130 days after
allo-HSCT (range, 41-994 days). The median interval
between CMV viremia and CMV disease viremia was
25 days (range, 0-123 days). In 5 of the 12 CMV
disease episodes (42%), CMV viremia was detected
Table 1. Characteristics of CMV Viremia and CMV Disease
after HSCT
Variable
Patients with CMV viremia, n 43
Episodes of CMV viremia, n 74
Median time of onset of first CMV viremia, days (range) 49 (13-479)
Median time of onset of CMV viremia, days (range) 81 (13-1240)
Patients with more than 1 episode of CMV viremia, n/N 16/43
2 episodes, n 8
3-7 episodes, n 8
First episode of CMV viremia beyond day +100, n/N (%) 5/43 (12)
Episodes of CMV viremia beyond day +100, n/N (%) 34/74 (46)
Patients with CMV disease, n/N (%) 9/43 (21)
Episodes of CMV disease, n/N (%) 12/74 (16)
Median interval from viremia to disease, days (range) 25 (0-123)
Median time of first CMV disease onset from HSCT,
days (range)
61 (13-199)
Median time of CMV disease onset from HSCT,
days (range)
130 (41-994)
First episodes of CMV disease beyond day +100, n/N (%) 2/9 (22)
Episodes of CMV disease beyond day +100, n/N (%) 5/12 (42)
Disease type, n
Pneumonitis 2
Gastroenteritis 3
Retinitis 7
Mortality related to CMV disease, n/N (%) 3/12 (25)
Pneumonitis 2/2
Gastroenteritis 1/3
Retinitis 0/7
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related to CMV disease was 25% (3 CMV-related
deaths among 12 CMV disease episodes). Two of the
fatal cases wereCMVpneumonitis and 1 casewasCMV
colitis; all 3 deaths were early CMV viremia cases. In-
cidence and mortality data are summarized in Table 1.
Risk Factors for CMV Disease
Univariate analysis was performed to compare
CMV viremia-only cases and viremia cases followed
by CMV disease. Comparisons of variables between
the 2 groups were assessed with the Fisher exact test,
considering the small sample size. Identified risk
factors for progression to CMV disease included
high viral load (P 5 .020), leukopenia (P 5 .012),
neutropenia at the detection of CMV viremia
(P 5 .033), and lymphopenia on day 100 post-HSCT
(P5 .027). The difference in initial viral load between
the viremia-only group and the CMV disease group
was statistically significant (median, 15,175 copies/
mL [range, 263–1,225,000] versus 78,750 copies/mL
[range, 155-485,000]; Mann-Whitney U test). When
episodes were subdivided into those with an initial viral
load#20,000 copies/mL and those with an initial viral
load .20,000 copies/mL, the higher viral load group
had a greater rate of CMV disease (25.6% versus
5.7%; P 5 .020). Seventeen episodes involved neutro-
penia or leukopenia at the time of detection of CMV
viremia, and viremia occurred after bone marrow en-
graftment following HSCT in 16 of these episodes.
The incidence of CMV disease was greater in patients
with neutropenia or leukopenia at detection of viremiathan in patients without neutropenia or leukopenia
(44.4% versus 12.3%, P 5 .033 for neutropenia;
40.0% versus 10.2%, P 5 .012 for leukopenia).
Patients with lymphopenia at day 100 post-HSCT
had a higher incidence of progression to CMV disease
compared with patients without lymphopenia at the
same time point (33.3% versus 9.8%; P 5 .027).
In this cohort, previously known risk factors for
CMV viremia, including donor type, alemtuzumab
or ATG treatment, and acute GVHD, did not influ-
ence the risk for progression to CMV disease. In addi-
tion, age, sex, intensity of conditioning, stem cell
source, early CMV viremia, high-dose steroid therapy
for GVHD, recurrent CMV viremia, anemia, lympho-
penia, monocytopenia, and thrombocytopenia were
not significant risk factors for progression to CMV
disease.
For multivariate analysis, the following covariates
were chosen based on a P value \.10 by univariate
Cox regression: high viral load (P 5 .048), leukopenia
(P 5 .008), neutropenia (P 5 .065), and lymphopenia
on day 100 post-HSCT (P5 .024). Donor type, alem-
tuzumab or ATG treatment, and acute GVHD were
also included in multivariate analyses as previously
known risk factors for CMV viremia despite having
P values ..10. Because of the strong correlation
among leukopenia, neutropenia, and lymphopenia on
day 100 post-HSCT, we evaluated the independent
effects of these 3 variables after adjustment for covari-
ates including the known risk factors for CMV viremia
in 3 separate models. On multivariate analysis, only
leukopenia at the time of detection of CMV viremia
had a significant effect on progression to CMV disease
(hazard ratio, 4.347; P 5 .045) (Table 2).
The cumulative incidence of CMV disease at 1
year post-HSCT was 42% in patients with leukopenia
and 27% in patients without leukopenia (P 5 .006).
The cumulative incidence of progression to CMV
disease by 6 months after detection of CMV viremia
was 57% in patients with leukopenia and 11% in
patients without leukopenia (P 5 .004) (Figure 1).
CMV Clearance after Preemptive Therapy
In 55 episodes, CMV viremia was cleared after 1
course of preemptive therapy. However, viremia
remained in 19 episodes and progressed to CMV
disease in 11 of these episodes (58%). In 4 episodes,
viremia cleared after an additional course of preemp-
tive therapy, 1 episode demonstrated self-clearance,
and the remaining 3 episodes resulted in death due
to another infection before clearance of viremia. All
12 episodes of CMV disease progression occurred
before the clearance of viremia. Eleven episodes of
CMV disease failed to respond to a single course of
preemptive therapy, and 1 episode progressed during
preemptive therapy. Factors associated with poor
CMV clearance included use of alemtuzumab or
Table 2. Multivariate Analysis of Risk Factors for Progression
from CMV Viremia to CMV Disease
Variable
Relative
Risk 95% CI
Corrected
P Value*
WBC #3000/mm3
Alemtuzumab/ATG 0.944 0.23-3.38 2.808
Donor type 3.003 0.37-24.30 .909
Acute GVHD 1.018 0.32-3.25 1.137
High viral load (>20,000 copies/mL) 4.489 0.97-20.78 .165
Leukopenia 4.347 1.33-14.25 .045†
Neutrophils #1500/mm3
Alemtuzumab/ATG 0.805 0.16-4.17 2.388
Donor type 3.24 0.4-26.15 .813
Acute GVHD 1.781 0.49-6.38 2.307
High viral load (>20,000 copies/mL) 3.180 0.67-15.02 .198
Neutropenia 3.139 0.83-11.89 .408
Day +100 lymphocytes #800/mm3
Alemtuzumab/ATG 1.184 0.28-4.97 2.451
Donor type 3.089 0.36-26.28 1.053
Acute GVHD 1.423 0.42-4.86 2.697
High viral load (>20,000 copies/mL) 2.966 0.63-13.94 .321
Lymphopenia on day +100 3.477 0.98-12.27 .159
Leukopenia, neutropenia, and lymphopenia were analyzed individually
because they were clearly associated with one another.
*Bonferroni-corrected P value for multiple comparisons.
†Statistically significant.
Table 3. Factors Influencing CMV Clearance after Pre-
emptive Therapy
Viremia
Cleared
(n 5 55), n (%)
Viremia
Remaining
(n 5 19), n (%) P Value
CMV disease <.001
Yes 1 (8.3) 11 (91.7)
No 54 (87.1) 8 (12.9)
Donor type .127
HLA-matched sibling 17 (89.5) 2 (10.5)
Alternative donor 38 (69.1) 17 (30.9)
Conditioning regimen .376
MA 28 (80.0) 7 (20.0)
NMA 27 (71.1) 11 (28.9)
Use of alemtuzumab/ATG .007
Yes 3 (33.3) 6 (66.7)
No 52 (80.0) 13 (20.0)
Acute GVHD .291
Present 25 (80.6) 6 (19.4)
Absent 30 (69.8) 13 (30.2)
High-dose steroid for GVHD .999
Yes 13 (76.5) 4 (23.5)
No 41 (71.9) 16 (28.1)
Recurrent viremia .697
Yes 26 (76.5) 8 (23.5)
No 29 (72.5) 11 (27.5)
Viral load .008
#20,000 copies/mL 31 (88.6) 4 (11.4)
>20,000 copies/mL 24 (61.5) 15 (38.5)
Leukopenia .002
WBC #3000/mm3 6 (40.0) 9 (60.0)
WBC >3000/mm3 49 (83.1) 10 (16.9)
Neutropenia .223
Absolute neutrophil
count #1500/mm3
5 (55.6) 4 (44.4)
Absolute neutrophil
count >1500/mm3
50 (76.9) 15 (23.1)
Lymphopenia .062
ALC #800/mm3 24 (64.9) 13 (35.1)
ALC >800/mm3 31 (83.8) 6 (16.2)
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viral load (38% .20,000 copies/mL versus 11.4%
#20,000 copies/mL; P 5 .008), leukopenia at detec-
tion of viremia (60.0% WBC #3000 versus 16.9%
WBC .3000; P 5 .002), and lymphopenia on day
100 post-HSCT (50% absolute lymphocyte count
[ALC] #800 versus 15.7% ALC .800; P 5 .009)
(Table 3).Figure 1. Kaplan-Meier estimate of the cumulative incidence of CMV
disease after the detection of CMV viremia according to leukopenia.
The 6-month cumulative incidence of CMV disease after the detection
of CMV viremia was 57% in patients with leukopenia and 11% in pa-
tients without leukopenia (P 5 .004).
Lymphopenia on day +100 .009
ALC #800/mm3 9 (50.0) 9 (50.0)
ALC >800/mm3 43 (84.3) 8 (15.7)
Early CMV viremia .697
#day +100 29 (74.3) 11 (27.5)
>day +100 26 (74.5) 8 (23.5)DISCUSSION
CMV infection and CMV-related organ damage
are often fatal infectious complications after allo-
HSCT. Although the risk factors for CMV viremia af-
ter solid organ transplantation or HSCT have been
studied extensively, little is known about the risk fac-
tors for progression to CMV disease from CMV vire-
mia. In this retrospective study, we evaluated the risk
factors for progression to CMV disease in episodes
of CMV viremia occurring in patients who received
preemptive therapy.
In this study, patients with initial high viral
load, leukopenia or neutropenia at detection of
viremia, and lymphopenia on day 100 post-HSCT
had significantly higher rates of progression to CMV
disease. Previous studies comparing a CMV-infected
group and a noninfected group found an association
between T cell immune reconstitution and CMV
Biol Blood Marrow Transplant 18:881-886, 2012 885Risk Factors for Progression of CMV Viremiaviremia/disease [1,4,5,12-16]. However, on univariate
analysis of our data, the variables interfering with
T cell immune reconstitution, including GVHD,
T cell–depleting agents, alternative donors, and
high-dose steroid therapy, did not have an impact on
progression to CMV disease. This discrepancy might
be explained by the difference between our study
groups (CMV viremia versus CMV disease) and the
study groups in previous reports (CMV-infected
patients versus noninfected control patients).
Barron et al. [16] reported strong associations
between the reconstitution of CMV-specific T cell
immunity and protection against CMV viremia, clear-
ance of viremia, and faster clearance of viremia. In our
study, episodes of CMV viremia associated with lym-
phopeniaonday100post-HSCThadahigh rate of pro-
gression to CMV disease, and when T cell–depleting
agents were involved, were associated with poor CMV
clearance even after preemptive therapy. This finding
suggests that the delayed reconstitution of T cell im-
munity is an important factor in the development of
CMV disease [17], although our multivariate analysis
did not demonstrate statistical significance.
Multiple studies have examined the appropriate
cutoff value of CMV viral load for starting antiviral
treatment [18,19]. Although some data suggest an
association between higher initial viral load and
higher incidence of CMV disease, there are no firm
data correlating viral load with the risk for
progression to CMV disease [20,21]. Our analysis
divided viremia episodes into high viral load
(.20,000 copies/mL) and low viral load (#20,000
copies/mL) on the basis of a receiver operating
characteristics curve analysis and examined
progression to CMV disease. Similar to other
reports, the group with the higher viral load had
greater CMV progression.
Several previous studies have suggested an associa-
tion between lymphopenia or CMV-specific T cell
deficiency after HSCT and CMV reactivation
[4,13,16]. Pi~nana et al. [15] reported that lymphopenia
at day 30 and/or day 120 post-HSCT is associated with
a high rate of progression to CMV disease. In our
study, lymphopenia on day 100 post-HSCT was
associated with CMV disease progression, and the
viremia episodes with lymphopenia before day 100
had a higher incidence of progression to CMV disease
(30% versus 5%; P 5 .091). However, among 74 total
viremia episodes, the time of viremia detection had no
statistical power, and lymphopenia at the time of
viremia detection was not a significant risk factor for
progression to CMV disease.
Because neutrophil and leukocyte counts are also
important in hematologic malignancies and other
serious infections [22], we examined the association
of neutropenia and leukopenia with progression to
CMV disease. Although both were found to be riskfactors by univariate analysis, only leukopenia
(WBC\3000 cells/mm3) had a statistically significant
effect in multivariate analysis. This finding led us to
conclude that the total WBC count at the time of
detection of CMV viremia is a more predictive variable
than either neutropenia or lymphopenia.
Leukopenia developing after allo-HSCT has
various possible causes, including the CMV viral
syndrome itself. Occasionally, hematologic abnormal-
ities such as leukopenia occur in CMV viral syndrome
without the presence of atypical lymphocytes [23].
This viral syndrome may be self-limited or may prog-
ress to clinically evident organ involvement. Thus,
leukopenia might not be the factor representing
patient immunity, but may be the factor reflecting viral
status. We confirmed that all of the 10 episodes of
leukopenia recovered, within a median of 8.2 days
(range, 1-24 days) after the first negative CMV PCR
result after preemptive treatment.
In the present study, CMV clearance after preemp-
tive therapy was affected by T cell–depleting agents,
lymphopenia on day 100 post-HSCT, high initial viral
load, and leukopenia at the time of CMV viremia
detection, and more than one-half of the episodes
with delayed clearance progressed to CMV disease.
But although alemtuzumab/ATG therapy affected
CMV clearance, it was not associated with CMV dis-
ease progression on univariate analysis, this finding
might be related to the small size of our dataset.
This study has several limitations. The sample
size is small, and data were collected retrospectively.
Because the patients for chart review were recruited
from a single transplant center, it was difficult to
create a sample with a large number of patients. Fur-
ther research with a larger sample size could provide
more definitive evidence. In addition, there may have
been patients with CMV disease who received
empirical therapy without pathological confirmation.
However, the relatively high statistical significance
of our results suggests that underreporting of
CMV disease incidence likely did not influence our
findings.
In conclusion, leukopenia is a notable risk factor
for progression to CMV disease from viremia, likely
due to poor clearance of CMV. Thus, intensification
of antiviral treatment and careful monitoring for onset
of CMV disease may be warranted in patients present-
ing with leukopenia at detection of CMV viremia.
Further prospective studies with larger patient cohorts
are needed to reconfirm our findings.ACKNOWLEDGMENTS
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